CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies - PubMed (original) (raw)
CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies
S Ogino et al. Gut. 2006 Jul.
Abstract
Background: The concept of CpG island methylator phenotype (CIMP) is not universally accepted. Even if specific clinicopathological features have been associated with CIMP, investigators often failed to demonstrate a bimodal distribution of the number of methylated markers, which would suggest CIMP as a distinct subtype of colorectal cancer. Previous studies primarily used methylation specific polymerase chain reaction which might detect biologically insignificant low levels of methylation.
Aim: To demonstrate a distinct genetic profile of CIMP colorectal cancer using quantitative DNA methylation analysis that can distinguish high from low levels of DNA methylation.
Materials and methods: We developed quantitative real time polymerase chain reaction (MethyLight) assays and measured DNA methylation (percentage of methylated reference) of five carefully selected loci (promoters of CACNA1G, CDKN2A (p16), CRABP1, MLH1, and NEUROG1) in 460 colorectal cancers from large prospective cohorts.
Results: There was a clear bimodal distribution of 80 microsatellite instability-high (MSI-H) tumours according to the number of methylated promoters, with no tumours showing 3/5 methylated loci. Thus we defined CIMP as having >or=4/5 methylated loci, and 17% (78) of the 460 tumours were classified as CIMP. CIMP was significantly associated with female sex, MSI, BRAF mutations, and wild-type KRAS. Both CIMP MSI-H tumours and CIMP microsatellite stable (MSS) tumours showed much higher frequencies of BRAF mutations (63% and 54%) than non-CIMP counterparts (non-CIMP MSI-H (0%, p<10(-5)) and non-CIMP MSS tumours (6.6%, p<10(-4)), respectively).
Conclusion: CIMP is best characterised by quantitative DNA methylation analysis. CIMP is a distinct epigenotype of colorectal cancer and may be less frequent than previously reported.
Figures
References
- Laird P W. Cancer epigenetics. Hum Mol Genet 200514R65–R76. - PubMed
- Kondo Y, Issa J P. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 20042329–39. - PubMed
- Rashid A, Issa J P. CpG island methylation in gastroenterologic neoplasia: a maturing field. Gastroenterology 20041271578–1588. - PubMed
- Issa J P. CpG island methylator phenotype in cancer. Nat Rev Cancer 20044988–993. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 CA087969/CA/NCI NIH HHS/United States
- R01 CA075090/CA/NCI NIH HHS/United States
- P01 CA055075/CA/NCI NIH HHS/United States
- P01 CA55075-13/CA/NCI NIH HHS/United States
- P01 CA87969-03/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous